More News! 6 May 2017 Color Patterns in the Clothes of the Future will be Made by Bacteria Natsai Audrey Chieza is an artist and researcher exploring the integration of life into the manufacturing of the materials of the future. Natsai Audrey Chieza wants to break with the current paradigm of fashion design and textile production with the help of microbiology. Her research focuses on developing bacterial biopigments for textiles to replace the […] May 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 3 May 2017 German Pharma Investigates Genetics of Pain to Personalize Treatment At the height of the opioid epidemic, Grünenthal has partnered up with 23andMe to explore the genetic factors associated with pain. Though opioid abuse has not been as rampant in Europe as it has in the United States, German pharma Grünenthal, which focuses on pain, inflammation and gout, has staked out a position in the fight. Today, […] May 3, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 8 Apr 2017 These Scientists are Turning the Human Brain into Art Neuroimaging artist duo DiMa takes the popular saying “beauty is inside” to another level by transforming complex visualizations of the brain into art. Diana Roettger and Matthew Rowe, who work together under the artistic name DiMa, are two imaging scientists that create art directly from scientific research. Originally from Germany and the UK, respectively, both hold […] April 8, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 7 Apr 2017 This Biotech Mining Probiotics to Treat the Skin has IPO’d in London SkinBioTherapeutics has raised £4,5M in its IPO on the London Stock Exchange to advance its probiotic technology for skin health applications. SkinBioTherapeutics, a spin-out from the University of Manchester, made its debut this week in AIM, the London Stock Exchange’s market for smaller growing companies. The £4,5M (€5.25M) raised will be used to continue the development […] April 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 6 Apr 2017 Fear & Loathing in GMOs: How do you change concerned minds? The house was packed to hear Joyce Tait of the Innogen Institute and Mark Lynas, an environmental writer, speak about smarter approaches to GM regulations. The second day of SynBioBeta yesterday started early, but fuelled by a passion for synthetic biology (on which a number of speakers commented), attendees packed into the lecture hall for a fireside chat on GMO regulation with Joyce […] April 6, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 4 Apr 2017 SynBioBeta Launches Venture Fund for Synthetic Biology Startups US-based venture capital fund Data Collective has announced that it is partnering with SynBioBeta to launch a new synthetic biology venture fund. Data Collective will join forces with SynBioBeta founder John Cumbers to launch the DCVC SynBioBeta fund, a pre-seed and seed VC fund to invest in synthetic biology startups. John Cumbers, an expert on […] April 4, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 3 Apr 2017 First Treatment for Severe Premenstrual Syndrome Clears Phase II Swedish Asarina Pharma has announced positive results of a Phase IIa study for the treatment of Premenstrual Dysphoric Disorder (PMDD). With only a single product candidate in its pipeline, Asarina Pharma is focusing on the development of the first potential therapy for the treatment of PMDD, a severe and disabling form of premenstrual syndrome that affects about 5% of […] April 3, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 1 Apr 2017 Will we Rely on Biomining to Build the Tech Devices of the Future? The Danish artist Jacob Remin explores how biotech might be essential if we want to keep building smartphones and laptops. Computers, tablets, phones, television screens… we take our electronic devices for granted. However, the rapidly increasing demand might not be possible to meet because of rare earth elements, a series of rare metals that are […] April 1, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 29 Mar 2017 More “FDA Love” for Cannabis Company with Orphan Drug Designation Last year was a doozy for biotech, but it was spectacular for GW Pharmaceuticals. Its streak continues with more special treatment. GW Pharmaceuticals, which is developing epilepsy treatments from marijuana, is making a name for itself not just as “that company” turning a recreational drug into medical ones; the company was also one of 2016’s surprise successes — its […] March 29, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 21 Mar 2017 Better than Quantum Computing: The EU Launches a Biocomputer Project The EU Horizon 2020 has launched Bio4Comp, a five-year €6.1M project to build more powerful and safer biocomputers that could outperform quantum computing. The Bio4Comp project has the ambitious goal of building a computer with greater processing speed and lower energy consumption than any of the most advanced computers existing today. Ultimately, this could translate into […] March 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 20 Mar 2017 UPDATE: Swiss Medtech cancels IPO and goes for Record €411M Exit UPDATE (10/04/2017): Symetis has decided to cancel its IPO following its acquisition by Boston Scientific in a €411M deal. The Swiss medtech company Symetis has launched a €55M IPO to accelerate the development of its next-generation heart valve replacement solutions. Symetis develops next-generation heart valve replacements for the treatment of cardiac valve conditions. With its […] March 20, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 9 Mar 2017 There’s a New Target for Anti-Aging Therapies According to a study at Queen Mary University of London (QMUL) published in the journal Cell Reports, the protein integrin-ß3 is a new marker and regulator of cellular senescence. Past research has revealed that the rising number of senescent cells, which appear during normal ageing, contributes to many age-related diseases. In a new study by Ana O’Loghlen and collegues, integrin-ß3 has been identified as […] March 9, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email